ArticleDiscover oncology2025
Efficacy and safety of PD-1 inhibitors combined with anti-angiogenic agents in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The evolution of EBV DNA as a biomarker in nasopharyngeal carcinoma immunotherapy: a bibliometric and knowledge mapping analysis.Virology journal · 2026Article
- Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesPD-1 inhibitors have shown significant progress in treating recurrent or metastatic nasopharyngeal carcinoma (R/M NPC); however, the optimal second-line regimen remains unclear. Studies have suggested that the combination of PD-1 inhibitors and anti-angiogenic agents shows synergistic potential in advanced nasopharyngeal carcinoma. This meta-analysis aims to assess the efficacy and safety of this combination therapy. MATERIALS AND
methodsWe performed an extensive search of PubMed, Embase, Cochrane Library, and Web of Science databases up to May 13, 2025. Stata 18.0 was used to analyze the eligible data.
resultsEight clinical trials involving 271 cases were included. The objective response rate (ORR) was 49% (95% CI: 39-59%), the disease control rate (DCR) was 80% (95% CI: 74-85%), the one-year progression-free survival rate (1-year PFS) was 39% (95% CI: 29-49%), and the one-year overall survival rate (1-year OS) was 73% (95% CI: 58-85%). The most common grade 3-4 adverse event was hypothyroidism, occurring in 36% of patients. Additionally, further subgroup analysis showed that combination therapy was more effective in patients who had not previously received PD-1 inhibitors (P = 0.003).
conclusionIn summary, PD-1 inhibitors combined with anti-angiogenic agents exhibited notable effectiveness with a manageable safety profile. Additional phase III randomized controlled trials (RCTs) are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.